Generic Name and Formulations:
Linagliptin 5mg; tabs.
Boehringer Ingelheim and Lilly
Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy. Limitations of use: not for treatment of type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
5mg once daily.
<18yrs: not established.
Dipeptidyl peptidase-4 inhibitor.
Monitor for signs/symptoms of pancreatitis; discontinue if suspected. Pregnancy (Cat.B). Nursing mothers.
Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.
Nasopharyngitis, hypoglycemia, arthralgia, back pain, headache; hypersensitivity reactions (eg, urticaria, angioedema, localized skin exfoliation, bronchial hyperreactivity), myalgia, pancreatitis.
Enterohepatic (80%), renal (5%).